TA
TARA.US Protara Therapeutics Inc
- Market cap
- USD 143M
- P/E
- -
- P/B
- 1.04x
- ROE
- -57.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is TARA.US undervalued?
Graham numberThe Graham number of Protara Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Protara Therapeutics Inc fundamental analysis
No fundamental analysis for Protara Therapeutics Inc yet.
Protara Therapeutics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Protara Therapeutics Inc
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for pa…
Full company profileProtara Therapeutics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Protara Therapeutics Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | - | - | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -123K | -148K | -115K | -16.0K | -196K | -1.17M | -247K | -341K | -332K | -362K | - |
| Operating Income | -28.7M | -30.4M | -26.1M | -15.3M | -34.4M | -47.5M | -67.1M | -43.6M | -49.2M | -64.5M | -88.1M |
| EBITDA | -28.4M | -29.8M | -20.6M | -7.81M | -33.8M | -45.4M | -64.6M | -40.1M | -44.3M | -57.1M | -81.2M |
| Net Income | -28.5M | -30.0M | -25.4M | -15.0M | -34.0M | -47.3M | -66.0M | -40.4M | -44.6M | -57.4M | -81.5M |
| EPS | -69 | -69 | -9.93 | -3.69 | -4.70 | -4.21 | -5.86 | -3.57 | -2.17 | -1.34 | -1.30 |
| Balance Sheet | |||||||||||
| Total Assets | 43.5M | 44.0M | 23.5M | 6.98M | 203M | 173M | 113M | 79.0M | 181M | 209M | 157M |
| Total Liabilities | 5.08M | 9.24M | 3.08M | 583K | 3.91M | 10.7M | 11.2M | 10.6M | 14.3M | 13.1M | 15.5M |
| Shareholders' Equity | 38.4M | 34.7M | 20.4M | 6.39M | 199M | 162M | 102M | 68.3M | 167M | 196M | 141M |
| Cash & Short-term Investments | 41.3M | 42.1M | 21.9M | 6.18M | 169M | 91.2M | 84.4M | 65.6M | 170M | 156M | 127M |
| Total Debt | - | 20.0K | - | - | 1.09M | 7.24M | 6.38M | 5.47M | 4.48M | 3.36M | 2.44M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -23.7M | -22.4M | -23.2M | -15.6M | -23.4M | -34.5M | -26.5M | -37.6M | -35.8M | -56.4M | -73.6M |
| Capital Expenditure | 271K | 35.0K | 119K | 16.0K | 884K | 596K | 120K | 45.0K | 63.0K | 94.0K | 1.41M |
| Free Cash Flow | -24.0M | -22.4M | -23.4M | -15.7M | -24.3M | -35.1M | -26.6M | -37.6M | -35.9M | -56.5M | -75.0M |
| Ratios | |||||||||||
| ROE | -74.2% | -86.3% | -124.4% | -234.5% | -17.1% | -29.2% | -64.6% | -59.2% | -26.7% | -29.2% | -57.8% |
| ROA | -65.5% | -68.1% | -108.1% | -214.9% | -16.7% | -27.4% | -58.2% | -51.2% | -24.6% | -27.4% | -52.1% |
| Debt to Equity | - | 0.00x | - | - | 0.01x | 0.04x | 0.06x | 0.08x | 0.03x | 0.02x | 0.02x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Protara Therapeutics Inc dividends
Protara Therapeutics Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:40 on Jan 10, 2020.
Who owns Protara Therapeutics Inc
- Insiders 2.21%
- Institutions 74.93%
- Public & others 22.86%
- Shares outstanding 61.6M
- Free float 57.4M
Top funds holding TARA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 1.66M | 2.76% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 1.33M | 2.22% | 0.00% | Oct 2026 |
| Columbia Small Cap Value Discv A | 768K | 1.28% | +0.73% | Sep 2026 |
| Biotech Growth Ord | 691K | 1.15% | +54.93% | Jul 2026 |
| Fidelity Small Cap Index | 569K | 0.95% | 0.00% | Aug 2026 |
| iShares Russell 2000 Value ETF | 514K | 0.86% | 0.00% | Oct 2026 |
| Vanguard Russell 2000 ETF | 312K | 0.52% | +4.08% | Sep 2026 |
| Fidelity Extended Market Index | 253K | 0.42% | -0.38% | Sep 2026 |
| DFA U.S. Small Cap I | 182K | 0.30% | 0.00% | Sep 2026 |
| iShares Micro-Cap ETF | 160K | 0.27% | 0.00% | Oct 2026 |
| DFA US Micro Cap I | 149K | 0.25% | +3.14% | Sep 2026 |
| Dimensional US Small Cap ETF | 135K | 0.23% | 0.00% | Oct 2026 |
| Columbia VP Small Cap Value Discovery 1 | 133K | 0.22% | 0.00% | Sep 2026 |
| Schwab Small Cap Index | 122K | 0.20% | -7.70% | Sep 2026 |
| Northern Small Cap Value | 118K | 0.20% | 0.00% | Sep 2026 |
| Stt Strt SPDR® Russell2000 US SmCapETF | 114K | 0.19% | -5.90% | Oct 2026 |
| iShares Russell 2000 Small-Cap Idx Instl | 96.0K | 0.16% | +14.99% | Sep 2026 |
| Avantis US Small Cap Equity ETF | 94.6K | 0.16% | 0.00% | Oct 2026 |
| Fidelity Total Market Index | 85.9K | 0.14% | -0.05% | Sep 2026 |
| Fidelity VIP Disciplined Small Cap Init | 81.1K | 0.14% | 0.00% | Aug 2026 |
Top institutions holding TARA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Jupiter Topco LLC | 4.70M | 7.83% | 0.00% | Jun 2026 |
| BlackRock Inc | 3.66M | 6.11% | +7.91% | Jun 2026 |
| Millennium Management LLC | 3.10M | 5.17% | +9.54% | Jun 2026 |
| Velan Capital Investment Management LP | 2.84M | 4.74% | +0.35% | Jun 2026 |
| Vanguard Capital Management, LLC | 2.30M | 3.84% | +8.55% | Jun 2026 |
| Blackstone Inc | 2.27M | 3.78% | 0.00% | Jun 2026 |
| Orbimed Advisors LLC | 2.22M | 3.70% | 0.00% | Jun 2026 |
| Sio Capital Management, LLC | 1.92M | 3.20% | -2.44% | Jun 2026 |
| Integral Health Asset Management, LLC | 1.50M | 2.50% | -14.29% | Jun 2026 |
| 5AM Venture Management, LLC | 1.37M | 2.28% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 1.33M | 2.21% | +12.66% | Jun 2026 |
| Citadel Advisors Llc | 1.23M | 2.06% | +15.33% | Jun 2026 |
| State Street Corp | 1.07M | 1.78% | +6.28% | Jun 2026 |
| Qube Research & Technologies | 1.05M | 1.74% | +490.67% | Jun 2026 |
| Balyasny Asset Management LLC | 1.03M | 1.71% | 0.00% | Jun 2026 |
| Baker Bros Advisors LP | 972K | 1.62% | 0.00% | Jun 2026 |
| ADAR1 Capital Management LLC | 941K | 1.57% | 0.00% | Jun 2026 |
| Bank of America Corp | 882K | 1.47% | -4.72% | Jun 2026 |
| Marshall Wace Asset Management Ltd | 701K | 1.17% | +1,281.84% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 684K | 1.14% | +0.13% | Sep 2026 |
Protara Therapeutics Inc company profile
- Company name
- Protara Therapeutics Inc
- Ticker
- TARA.US
- Exchange
- USA Stocks
- Listed since
- Oct 22, 2014
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 46
- Fiscal year end
- December
- Address
- 345 Park Avenue South, New York, NY, United States, 10010
- Phone
- 646 844 0337
- Website
- protaratx.com
About Protara Therapeutics Inc
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for patients receiving parenteral nutrition and fluids. The company is headquartered in New York, New York.
Protara Therapeutics Inc management
10- Mr. Jesse SheffermanCo-founder, CEO, President & Director · born 1972
- Dr. Jacqueline Zummo M.B.A., M.P.H., Ph.D.Co-Founder, Chief R&D Officer · born 1981
- Mr. Patrick Fabbio M.B.A.Chief Financial Officer · born 1968
- Ms. Hannah FryVP, Principal Accounting Officer & Controller · born 1991
- Ms. Justine O'MalleySenior Vice President of Investor Relations & Corporate Affairs
- Ms. Mary J. Grendell J.D.General Counsel & Corporate Secretary
- Dr. Shane Williams Ph.D.Chief People Officer
- Mr. William ConklingChief Commercial Officer · born 1971
- Carla Beckham M.D., Ph.D.Lead Medical Director, Head of Clinical Development of TARA-002 in NMIBC & Board-Certified Urologist
- Dr. Neal D. Shore F.A.C.S., M.D.Medical Director of START Carolinas/ Carolina Urologic Research Center